Compare YSXT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | ENTX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 147.4M |
| IPO Year | 2023 | 2015 |
| Metric | YSXT | ENTX |
|---|---|---|
| Price | $1.30 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 20.0K | ★ 380.0K |
| Earning Date | 02-03-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.22 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $5.57 | $12.77 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.50 | $0.91 |
| 52 Week High | $3.14 | $4.20 |
| Indicator | YSXT | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.24 | 44.09 |
| Support Level | $0.98 | $2.71 |
| Resistance Level | $1.51 | $3.10 |
| Average True Range (ATR) | 0.10 | 0.17 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 58.97 | 21.28 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.